ARTICLE | Company News
Biotie autoimmune, pulmonary news
January 3, 2011 8:00 AM UTC
Biotie restructured and reduced headcount by 59 (73%) to 22 as part of its previously announced plans to discontinue its early-stage discovery efforts in order to focus on the clinical development of ronomilast and BTT-1023. Biotie spun-off its Radebeul, Germany, site into newco, biocrea GmbH, and moved all operations to its Turku, Finland, headquarters (see BioCentury, Nov. 1, 2010 & Nov. 15, 2010). ...